Amgen Inc. (ETR: AMG)

Market Cap	135.91B
Revenue (ttm)	29.17B
Net Income (ttm)	3.79B
Shares Out	n/a
EPS (ttm)	7.02
PE Ratio	35.84
Forward PE	n/a
Dividend	8.35 (3.36%)
Ex-Dividend Date	Feb 14, 2025

Volume	4,288
Open	251.05
Previous Close	248.75
Day's Range	251.00 - 263.55
52-Week Range	243.30 - 318.05
Beta	0.60
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 4, 2025

About Amgen

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; N...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1980
• Employees: 26,700
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: AMG

Financial Performance

In 2023, Amgen's revenue was $28.19 billion, an increase of 7.09% compared to the previous year's $26.32 billion. Earnings were $6.72 billion, an increase of 2.52%.

Financial numbers in USD